RUNX1T1
RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Leukaemia, Hepatocellular carcinoma and 5 more.
Overview
Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes. Can repress the expression of MMP7 in a ZBTB33-dependent manner. Can repress transactivation mediated by TCF12.
Open Targets scores its association with cancer at 0.69 (direct and indirect evidence; datatypes literature 0.99, animal model 0.30, genetic association 0.32, somatic mutation 0.87). IntOGen calls it a driver in 7 cohorts (4 activating, 3 loss-of-function), covering Hepatocellular Carcinoma, Low-Grade Glioma, NOS, Lung Squamous Cell Carcinoma, Melanoma, Prostate Adenocarcinoma, Small Cell Lung Cancer.
- Target · the protein and the cell it sits on
- Drug · antibody, small molecule, cell or radioligand
- Effect · signal, damage or kill
In plain words · RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Leukaemia, Hepatocellular carcinoma and 5 more.
- 1 · What it is
RUNX1T1 (RUNX1 partner transcriptional co-repressor 1) is a protein that switches other genes on and off. The public catalogues list it as an oncogene driver, a tumour suppressor and a fusion partner, and it is called a cancer driver by mutation analysis of patient cohorts. Tied to Lung cancer, Leukaemia, Hepatocellular carcinoma and 5 more.
- 2 · What goes wrong in cancer
Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes.
- 3 · How drugs use it
No product in this corpus aims at RUNX1T1 yet. Transcription factors have no pocket to plug, so drugs either degrade them or block the partner protein they need to dock on DNA.
External identifiers
Sources: HGNC HGNC:1535 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt Q06455 (protein name, function text, keywords and locations (REST API)); Open Targets ENSG00000079102 (association with cancer (MONDO_0004992) 0.69; per-cancer scores at or above 0.5: melanoma 0.59, acute myeloid leukaemia 0.51, non-Hodgkin lymphoma 0.52, skin cancer 0.55, myeloproliferative neoplasm 0.52, breast cancer 0.54 (GraphQL API, CC0)); IntOGen RUNX1T1 (driver in 7 cohorts (Act 4, LoF 3); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
Biology
Transcriptional corepressor which facilitates transcriptional repression via its association with DNA-binding transcription factors and recruitment of other corepressors and histone-modifying enzymes. Can repress the expression of MMP7 in a ZBTB33-dependent manner. Can repress transactivation mediated by TCF12. Acts as a negative regulator of adipogenesis. The AML1-MTG8/ETO fusion protein frequently found in leukaemic cells is involved in leukemogenesis and contributes to haematopoietic stem/progenitor cell self-renewal. Location: Nucleus (UniProt). Locus 8q21.3 (HGNC).
- Lung cancer: Open Targets association 0.58 with lung cancer (MONDO_0008903)
- Leukaemia: Open Targets association 0.57 with leukaemia (MONDO_0005059)
- Hepatocellular carcinoma: IntOGen driver in 1 cohort (HCC)
- Prostate cancer: IntOGen driver in 1 cohort (PRAD)
- Skin cancer: Open Targets association 0.55 with skin cancer (MONDO_0002898)
- Breast cancer: Open Targets association 0.54 with breast cancer (MONDO_0007254)
Notes
top- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: IntOGen calls it an activating (Act) driver in 4 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 3 cohorts; UniProt disease notes describe a translocation or gene fusion involving the gene. Evidence tier "cohort-driver" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.
- Diseases the sources name that have no OnCo cancer page yet, so they are not linked: Low-Grade Glioma, NOS.
Latest papers
topQuery for this target: (TITLE:"RUNX1T1" OR ABSTRACT:"RUNX1T1" OR TITLE:"RUNX1 partner transcriptional co-repressor 1" OR ABSTRACT:"RUNX1 partner transcriptional co-repressor 1" OR TITLE:"MTG8" OR ABSTRACT:"MTG8" OR TITLE:"ZMYND2" OR ABSTRACT:"ZMYND2" OR TITLE:"AML1T1" OR ABSTRACT:"AML1T1" OR TITLE:"CBFA2T1" OR ABSTRACT:"CBFA2T1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about RUNX1T1, not a curated reading list.
Similar pages
not linked directly; found by shared links- TargetCUX1
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetEPS15
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetCLTCL1
Shares Lung cancer (all types), Skin cancer (all types), Hepatocellular carcinoma, Breast cancer (all types).
- TargetLEF1
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Hepatocellular carcinoma.
- TargetTRIM24
Shares Leukaemia (all types), Lung cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).
- TargetCBFA2T3
Shares Myeloproliferative neoplasms (PV, ET, myelofibrosis), Leukaemia (all types), Lung cancer (all types), Skin cancer (all types).
- TargetPAX5
Shares Leukaemia (all types), Lung cancer (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types).
- TargetSUZ12
Shares Leukaemia (all types), Skin cancer (all types), Non-Hodgkin lymphoma (all types), Breast cancer (all types).